Cas:651744-27-3 4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine manufacturer & supplier

Chemical Name:4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine

CAS.NO:651744-27-3

Synonyms:1h-pyrrolo[2,3-b]pyridine,4-fluoro-2-methyl

Molecular Formula:C₈H₇FN₂

Molecular Weight:150.15300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:286.706ºC at 760 mmHg

Density:1.299g/cm3

Index of Refraction:1.636

PSA:28.68000

Exact Mass:150.05900

LogP:2.01040

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1h-pyrrolo[2,3-b]pyridine,4-fluoro-2-methyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1h-pyrrolo[2,3-b]pyridine,4-fluoro-2-methyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1h-pyrrolo[2,3-b]pyridine,4-fluoro-2-methyl Use and application,1h-pyrrolo[2,3-b]pyridine,4-fluoro-2-methyl technical grade,usp/ep/jp grade.

Related News: In March 2021, Reuters reported that a former Lilly human resources officer, Amrit Mula, had identified internally some of the same violations later documented by the FDA. Mula was forced out of the company in early 2019 after Lilly executives sought to downplay her findings, according to a letter demanding compensation for damages that her attorneys sent to the company. 4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine manufacturer There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space. 4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine supplier In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine vendor In its message to the public, the FDA said that a person should consider being retested if they used Innova’s diagnostic within the past two weeks. 4-fluoro-2-methyl-1H-pyrrolo[2,3-b]pyridine factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��